Effects Of Probiotics And Lactoferrin On Necrotizing Enterocolitis In Preterm Infants

BackgroundNecrotizing enterocolitis (NEC) is a leading cause of morbidity and mortality in neonates. Despite intensive research, the etiology and pathophysiology of NEC is still obscure. Evidence from recent studies and meta-analyses showed a significant role of probiotics as a prophylactic measure in reducing NEC, sepsis, and mortality. However, obstacles against the generalization of the results still remain. The aim of the study was to evaluate the role of prophylactic administration of probiotics and lactoferrin in reducing the rate of NEC in preterm infants.MethodsIn this retrospective cohort study, all medical records of infants born with a birth weight of 1,500 g and less who were born between 2012 and 2017 were reviewed. The enrolled infants were divided into two groups: group 1 included infants born between January 2012 and August 2014, a period before probiotics were started in our unit, and group 2 included infants born between January 2014 and December 2017 after starting probiotics and lactoferrin. Multiple variables were collected including maternal data, neonatal data, and risk factors for NEC.ResultsMedical records of 284 infants who met our inclusion criteria were reviewed. Of the 284 infants, 150 infants were in group 1 and 134 were in group 2. There were no significant statistical differences between group 1 and group 2 in neonatal and maternal demographic data and clinical data. Of 134 infants who received probiotics and lactoferrin, 11 developed NEC, while 26 of the 134 infants in group 1 developed NEC, and the difference was statistically significant (p = 0.023).ConclusionProbiotics and lactoferrin given orally to very low birth weight preterm infants were associated with a decreased rate of NEC.